VOLITIONRX LTD — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
VolitionRx reported Q2 2026 revenue of $0.4M (flat YoY), H1 2026 revenue of $1.4M (112% growth YoY). Operating loss of $4.2M improved 34% YoY. Company raised $5.3M in Q2 (equity ATM $1.2M + offering $4.1M). Management stated it is in discussions with >12 diagnostic companies for licensing agreements targeting upfront and recurring revenue, with a potential $5M milestone payment tied to peer-reviewed publication of feline lymphoma test expected later.
Why this rating
Early-stage biotech with flattening quarterly revenue, improving losses, and speculative licensing pipeline. Raised capital is modest relative to $73M market cap; milestone payments uncertain and forward-looking.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.